Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019
October 2019
100
About the Report
About the Report
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q2 2019
Summary
GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q2 2019 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Products
Products
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
Table of Contents
Table of Contents
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2019
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2019
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2019
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2019
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2019
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2019
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2019
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2019
3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2019
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2019
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2019
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2018-Q2 2019
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (USD m), Q2 2019
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2018-Q2 2019
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (USD m), Q2 2018-Q2 2019
4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2019
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2019
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (USD m), Q2 2018-Q2 2019
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (USD m), Q2 2018-Q2 2019
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), Q2 2018-Q2 2019
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), Q2 2018-Q2 2019
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (USD m), Q2 2018-Q2 2019
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2019
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2019
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2019
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2019
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2019
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2019
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2019
6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2019
6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2019
6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2019
7 Deal Summary by Geography
7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2019
7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2019
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2019
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2019
8 Pharmaceuticals & Healthcare, Global, Top Advisors
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q2 2018-Q2 2019
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q2 2018-Q2 2019
9 Further Information
9.1 Methodology
9.2 About GlobalData
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer
List of Figure
List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2019 12
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q2 2019 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 18
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q2 2018-Q2 2019 20
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 21
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 23
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 25
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q2 2019 26
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q2 2019 27
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q2 2018-Q2 2019 28
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 29
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 31
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q2 2018-Q2 2019 32
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 34
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 36
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (USD m), Q2 2018-Q2 2019 37
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), Q2 2018-Q2 2019 39
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2018-Q2 2019 40
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2018-Q2 2019 41
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (USD m), Q2 2018-Q2 2019 42
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 44
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019 45
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 48
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019 49
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q2 2018-Q2 2019 51
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (USD m), Q2 2018-Q2 2019 52
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019 53
Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 55
Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 59
Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 62
Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 65
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 68
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 71
Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 74
Figure 36: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 77
Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 79
Figure 38: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 81
Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 84
Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 87
Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 90
Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 93
Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 96
Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 97
List of Table
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 11
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2019 13
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2019 14
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 19
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2019 19
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, , Q2 2018-Q2 2019 20
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 22
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2019 22
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2019 22
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2019 23
Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 24
Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 25
Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2019 26
Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2019 27
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 28
Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 29
Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2018-Q2 2019 30
Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 31
Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2019 32
Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 33
Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 35
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 36
Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019 37
Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (USD m), Q2 2019 38
Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2019 38
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2019 38
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), Q2 2018-Q2 2019 39
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2018-Q2 2019 41
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (USD m), Q2 2018-Q2 2019 43
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 44
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (USD m), Q2 2018-Q2 2019 45
Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2019 46
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2019 46
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2019 47
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 48
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (USD m), Q2 2018-Q2 2019 50
Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2018-Q2 2019 52
Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (USD m), Q2 2018-Q2 2019 54
Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 56
Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 60
Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 63
Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 66
Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 69
Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 72
Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 75
Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 78
Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 80
Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 82
Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 85
Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 88
Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 91
Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 94
Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 96
Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), Q2 2018-Q2 2019 97
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.